Pharmaceutical Innovation Partners
Accelerate Clinical Research with AI-Powered Patient Identification
Lavaa supports pharmaceutical and biotech companies in bringing life-changing treatments to patients faster. With AI-driven risk scoring and a research-ready development environment, we help teams streamline clinical trial recruitment and power breakthrough discoveries.
Intelligent Patient Matching
Advanced Risk Profiling
Our system intelligently flags patients with rare or hard-to-diagnose chronic conditions, enabling access to patient access programs or advanced treatment options earlier in the disease journey.
Built for Global Collaboration
As a SaaS platform, Lavaa facilitates secure, cross-border research collaboration—empowering pharmaceutical companies to scale innovation across markets and care systems.
Partner-Driven Engine Development
Through Lavaa’s Interactive Development Environment, research teams can build condition-specific engines to support their therapeutic focus—accelerating peer-reviewed results and commercial readiness.
Key Features for Pharma Teams
- Risk scoring engines for 40+ disease areas
- Rare disease detection for trial recruitment
- Real-time eligibility tracking
- Secure data pipeline and compliance support
- Custom module creation with Lavaa’s IDE
Working with Lavaa for Pharmaceutical Research
Frequently Ask Questions
Explore how Lavaa’s platform supports faster, smarter clinical research and patient access programs.
Lavaa uses AI-powered engines to analyze EMR and population health data in real time, identifying patients who meet specific eligibility criteria for rare or hard-to-diagnose conditions—helping pharma teams accelerate recruitment for Phase-3 trials.
Yes. Lavaa is fully compliant with HIPAA, SOC 2, and ISO 27001/27701 standards. We do not store PHI, and all data is encrypted with strict access controls.
Lavaa supports over 40 chronic and rare conditions, with modules continuously under development. From endometriosis to Fabry disease, our engines can be tailored to your therapeutic priorities.